After Hours
$
7.50
Change
0.00 0.00%
Volume
Volume 154,896
Jun 24, 2022, 5:00 p.m.
Quotes are delayed by 20 min
Previous close
$ 7.39
$ 7.50
Change
+0.11 +1.49%
Day low
Day high
$7.22
$7.66

52 week low
52 week high
$5.60
$19.32

Market cap
$580.67M
Average volume
1.12M
P/E ratio
N/A
Rev. per Employee
$914,554
EPS
-2.72
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on CHRS
-
Coherus BioSciences started at neutral with $7 stock price target at UBS
- Tomi Kilgore
-
Coherus BioSciences stock price target cut to $25 from $30 at Mizuho
- Tomi Kilgore
-
Coherus BioSciences downgraded to neutral from overweight at J.P. Morgan
- Tomi Kilgore
-
Coherus BioSciences stock price target cut to $30 from $35 at Mizuho
- Tomi Kilgore
-
Coherus BioSciences started at buy with $26 stock price target at SunTrust RH
- Tomi Kilgore
-
2 Drug Stocks to Buy as Health Care Suffers, According to JPMorgan
- Barron's Online
-
Fending Off Rivals, Amgen Posts Better Than Expected Sales
- Barron's Online
-
How to spot risky biotech companies and six to avoid now
- Michael Brush
-
Coherus Biosciences stock price target raised to $25 from $22 at Maxim Group
- Tomi Kilgore
-
After Correction Pain, More Market Gain?
- Barron's Online
-
- Barron's Online
-
Amgen’s rival to AbbVie’s Humira to launch in 2023
- Emma Court
-
AbbVie: Has the Humira Cloud Lifted?
- Barrons Blogs
-
Coherus BioSciences stock drops 27% after drug wasn't approved by FDA
- Emma Court
-
AbbVie: It’s the Pipeline, Not the Coherus Ruling
- Barron's Online
- Loading more headlines...
Analyst Ratings
-
UBS Downgrades AbbVie; Here's What Changed Analysts' View
- Benzinga.com
Other News on CHRS
-
Coherus: Will Its Chinese Gambit Fail?
- Seeking Alpha
-
Outlook Healthier For Key Chinese Sector
- Seeking Alpha
-
10-Q: COHERUS BIOSCIENCES, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
Notable earnings after Thursday's close
- Seeking Alpha
-
Coherus, Junshi hit by FDA rejection of cancer therapy
- Seeking Alpha
-
Coherus BioSciences (CHRS) Investor Presentation - Slideshow
- Seeking Alpha
-
Coherus gains after issuing long-term guidance
- Seeking Alpha
-
Coherus Biosciences (CHRS) Investor Presentation - slideshow
- Seeking Alpha
- Loading more headlines...
Press Releases on CHRS
-
Coherus BioSciences Announces New Employment Inducement Grants
- GlobeNewswire
-
Coherus BioSciences Reports First Quarter 2022 Results
- GlobeNewswire
-
Coherus BioSciences Announces New Employment Inducement Grants
- GlobeNewswire
-
Coherus BioSciences Announces New Employment Inducement Grants
- GlobeNewswire
-
Coherus Management to Present at Upcoming Investor Conferences
- GlobeNewswire
-
Coherus Names Paul Reider Chief Commercial Officer
- GlobeNewswire
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com